AHMEMZO
Live / Applied — First extension granted (statement of use) (as of 12 Dec 2025)
What this means for you
Not registered yet, but its 31 Oct 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98247807
- Mark type
- Stylized text
- Filed
- 31 Oct 2023
- Published for opposition
- 13 May 2025
- Attorney of record
- Xiomara Triana
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T-Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical and clinical use; Pharmaceutical preparations for human use for the treatment and prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment and prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic agents, preparations and substances for medical purposes for human use; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer for human use; pharmaceutical preparations for human use in the nature of radio-isotope markers for therapeutic and diagnostic use.
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, Princeton, NJ, US
Prosecution history
- 13 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Dec 2025 — SOU EXTENSION 1 GRANTED
- 12 Dec 2025 — SOU EXTENSION 1 FILED
- 12 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 08 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 May 2025 — PUBLISHED FOR OPPOSITION
- 07 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 10 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 10 Mar 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 13 Feb 2025 — NOTIFICATION OF SUBSEQUENT FINAL EMAILED
- 13 Feb 2025 — CONTINUATION OF FINAL REFUSAL E-MAILED
- 13 Feb 2025 — ACTION CONTINUING A FINAL - COMPLETED